

EHA Scientific Workshop  
**The Role of Epigenetics in Hematological Malignancies**  
 Chairmen: J.-P. Issa, M. Esteller, M. Lübbert  
 Dates: February 9-11, 2007  
 Venue: Sofitel Royal Casino, Mandelieu, France

**PROGRAMME**

**FRIDAY, FEBRUARY 9, 2007**

3.30 pm            *Registration*

**Session 1: Epigenetics and cancer– An Overview**

|              |   |                                 |
|--------------|---|---------------------------------|
| 5:00-5:15 pm | Introduction  | Jean-Pierre Issa (Houston, USA) |
| 5:15-6:10 pm | Rediscovering gene expression: Epigenetic instabilities in cancer | Jean-Pierre Issa (Houston, USA) |
| 6:10-7:05 pm | DNA methylomes and histone modification maps                      | Manel Esteller (Madrid, Spain)  |
| 7:05-8:00 pm | Epigenetic medicine: Prospects and thoughts about heritability    | Bryan Turner (Birmingham, UK)   |

8:00 pm            *Welcome cocktail  
Dinner*

**SATURDAY, FEBRUARY 10, 2007**

**Session 2: Epigenetics of Hematologic Malignancies**

|                |  |                                      |
|----------------|--|--------------------------------------|
| 8:00-8:30 am   | How the epigenome changes in cancer  | Peter Jones (Los Angeles, USA)       |
| 8:30-9:00 am   | Promoter region methylation in MDS/AML   | James Herman (Baltimore, USA)        |
| 9:00-9:30 am   | DNA methylation in myelodysplastic syndrome:<br>Biomarkers to predict prognosis and responses to epigenetic therapy    | Lanlan Shen (Houston, USA)           |
| 9:30-10:00 am  | Global DNA methylation in chronic lymphocytic leukemia (CLL)   | Christoph Plass (Columbus, USA)      |
| 10:00-10:15 am | <i>Coffee break</i>  |                                      |
| 10:15-10:45 am | Differential patterns of DNA methylation in lymphoid malignancies  | Charles Caldwell (Columbia, USA)     |
| 10:45-11:15 am | DNA methylation in myeloproliferative diseases   | Jaroslav Jelinek (Houston, USA)      |
| 11:15-11:45 am | Effects of oncogenic fusion proteins on chromatin  | Pier Giuseppe Pelicci (Milan, Italy) |
| 11:45-12:15 pm | Chromatin alteration in tumorigenesis  | Saverio Minucci (Milan, Italy)       |
| 12:15-1:00 pm  | Three oral communications  |                                      |
| 1:00-2:30 pm   | <i>Lunch</i>   |                                      |
| 2:30-5:00 pm   | Poster session   |                                      |
| 5:00-5:30 pm   | Exceeding the speed limit: Epigenetics, elongation and ENL as cues to understand transformation by MLL fusion proteins | Robert Slany (Erlangen, Germany)     |
| 5:30-6:00 pm   | Transcriptional dysregulation in AML   | Stephen Nimer (New York, USA)        |

|              |  |                                      |
|--------------|--|--------------------------------------|
| 6:00-6:30 pm | Epigenetic targets in acute myeloid leukemia   | Clara Nervi (Rome, Italy)            |
| 6:30-7:00 pm | Mechanistic insights into priming and early gene activation processes in the haemopoietic system | Constanze Bonifer (Leeds, UK)        |
| 7:00-7:30 pm | Identification and characterization of chromatin modifying enzymes in cancer                     | Kristian Helin (Copenhagen, Denmark) |
| 8:00 pm      | <i>Dinner</i>  |                                      |

|                                  |
|----------------------------------|
| <b>SUNDAY, FEBRUARY 11, 2007</b> |
|----------------------------------|

**Session 3: Epigenetic Therapy**

|                |   |  |
|----------------|---|--|
| 8:00-8:30 am   | 5-Aza-2'-deoxycytidine (Decitabine, Dacogen):<br>Future potential for therapy of hematological malignancies       | Richard Momparler (Montreal, Canada)   |
| 8:30-9:00 am   | Epigenetic therapy for MDS; who is candidate for Decitabine ?   | Pierre Wijermans (The Hague, Netherlands)  |
| 9:00-9:30 am   | Avoiding tunnel vision: Do current therapies targeting epigenetics work through epigenetic mechanisms?            | Steven Gore (Baltimore, USA)   |
| 9:30-10:00 am  | Low-dose treatment of AML and MDS with epigenetic therapy:<br>Which targets are hit?                              | Michael Lübbert (Freiburg, Germany)  |
| 10:00-10:15 am | <i>Coffee break</i>   |  |
| 10:15-10:45 am | Combination epigenetic therapy in leukemia and MDS  | Guillermo Garcia-Manero (Houston, USA)   |
| 10:45-11:15 am | Epigenetic immunomodulation of solid tumors:<br>A novel therapeutic approach also for hematological malignancies? | Michele Maio (Siena, Italy)  |
| 11:15-12:00 pm | Three oral communications   |  |
| 12:00-1:00 pm  | Wrap-up and discussion  | Jean-Pierre Issa (Houston, USA)<br>Manel Esteller (Madrid, Spain)<br>Michael Lübbert (Freiburg, Germany) |
| 1:00 pm        | <i>Lunch</i>  |  |